for core III Phase It recruitment QX We the Michael, you, progress namely a joining everybody, trial evening. on significant in on thank to remaining for and been complete us priorities, has quarter enrollment and track this you, XXXX. our on advancing Biotherapeutics. Thank really productive our of very made Eleven pivotal
a also without to capital. our we equity month important of top mid-XXXX that need release additional sufficient to very data addition, gives support three that In trial financing us from raise completed cash to the runway line
checkpoint inhibitor. the XXXX. Bio We believe all is Cancer the completed to lastly, Vicinium We combination of AstraZeneca’s complete these And of the with National continued Eleven and also now of trial positioned with and we needed heading work each manufacturing the into well trials. Institute our Vicinium
TPTs to end on that into is an cell payload cells, Targeted in internalization missile antibody-drug the navigating a the as same of cancer oncology concept therapeutics. concept binding They targeting released Let’s incorporate TPT the it. candidate, of known is dig which into that the antigen details. on are cell platform. molecule brings front-end, lead to is specific based that some or a marker smart or cancer cytotoxic a or ADCs, are product Protein of Therapeutics, original on our based Vicinium, proprietary which as the reminder, conjugates, over-expressed our after an were basic kill
ADCs these next-generation over those significant has TPT materially platform first-generation our advantages believe ADCs clinical some successes, some expand had While the we impact. have that could
TPTs We into smaller, the advantages believe single-chain and utilize better include, than ADCs. antibody penetrate can fragments. Fvs they Specifically, tumor antibody-based large our those bed
quiescent Second, unlike are necessary cancer this which of are the not primarily TPTs is Furthermore, inhibit allows in to that our effective. dividing We rapidly cells. most ADCs, dividing payloads cancer the TPT which to or dividing can our in which to payloads both cells. make subject protein cells, the are cell-like believe survival kill that non-dividing synthesis, effective our less TPT rapidly and ADCs used is resistance mechanisms, against cells payloads designed stem multi-drug for
us immunogenic our payloads to called cell Third, known the death, immune cancer response have clinical This TPTs exciting And manufacturing allows a supported preclinical the death human idea and data that spark trial cell type molecules. to lastly, which protein single by TPTs is our of proprietary is construct certain an cells. an of suggesting as system both also dual against four, our mechanism action. promote
consistency conjugate various these a to medical across these We need. fall do to benefit a set us candidates advantages apart up to unmet families. not products have make a believe variety like and cheaper As potentially clinical patients or result, meaningful for higher provide of product the antibody-drug
are or domain utilizes with in of on non-muscle targeting releases patients its protein selectively is, Let’s Pseudomonas to cancer high-grade to the very synthesis, to leading into fragment potent cytotoxic way to A, Exotoxin the Vicinium anti-EpCAM responding of for administered which that these binds ETA cell. payload a cancer the an bladder, death is go where who is Vicinium directly genetically development bladder is then the antibody into it Vicinium cells, fused BCG. the payload. not internalized ETA, is back BCG is treatment invasive EpCAM cells. and interrupts Vicinium. tumor same the Vicinium
bladder a invasive good cancer that and bladder area significant setting Importantly, potentially believe non-muscle for no normal non-muscle to this Targeted of these Vicinium little High cells. a perfect expressed a unmet for cells in muscle for cancer medical of option succeed setting is really a to is platform, our is invasive Protein on high-grade patients. is expression need. EpCAM to – therapeutic We this do as XX% bladder
in fact, bladder patients who associated options limited. of mortality. the surgery have A viable that in a the are alternatives. And removals responding with past, for treatment approximately the surrounding are and with refuse XX,XXX to surgery. asking cystectomy that result, undergo responding as surgery it’s that’s cystectomies or patients, are tissues. and There twice the American significant refuse is or bladder the number patients states, the projected the the discussed in a year believe lack Association on space, Due space. in morbidity FDA in the who to we this therapeutic And medical of importantly, the closely many life-changing out a this are guidance. we’ve BCG, other As unmet trial to groundwork actually BCG drugs follows not with came drug removal cystectomy and development Reflecting and laying this the stopped specific patients recommends very NMIBC, draft of design need, guidance for Neurology our approved the
in endpoint Our study’s CIS. patients complete or carcinoma-in-situ, response is Phase primary with III
U.S. the of these sites out of Canada. in patients XX enrolling and trial our We’re
the arms, treatments receive In six months. other If XX to – where no no and a for refractory one, study, evidence complete weekly At arm. in which achieve of patients to significant for months, trial, still arm If drive weekly two and one disease, our six year, Our which for they was had response three the a Phase Phase rate XX move current evidence or is showed in induction to to XX% then they on results II safety in XX were Vicinium builds II induction Vicinium that of received weeks, the The patients weeks. promising space. the the dosing that from to receive Phase maintenance, intolerant in at XX% of the III patients and response, who efficacy XX week again, XX in up disease, a and complete able meaning CR week of they a they BCG. were patients, response,
at the the week week and at follow-up recurrence XXX arm CR to arm. six Importantly, remained the in week all to up XX Median XX of time is arm patients in days XX months. last disease-free XXX
on recruitment are XXXX QX top in data the mid-XXXX. month to three and in line report We track complete
than We We approaching a as expect our results from that we regarding better Phase are FDA for to the Vicinium. the trial our potential patients. study and believe II finalizing study, which will to potential or similar achieve these look forward Vicinium’s results support therapeutic approval will alternative
to our introduction you’re patients. Adams, the to is aware role turn quite Science immuno-oncology excitement and Dr. treatment the going Officer, space. evolving we’ll recent all our provide exciting what cancer in and to an conversation around I’m the to the pass off Now he’ll I’m the treatment paradigms and sure development for Greg Chief of this
